India’s Bangalore-based Biocon has decided that it will be divesting its stake in the German drug distributor, AxiCorp GmbH. Some three years back it had taken up controlling stake in the company and now it will be selling the shares to the minority shareholders of the company.
AxiCorp as a company deals with marketing and distribution of various products related to the healthcare industry. It was started by a group of industry professionals in 2002, who wanted to milk the distribution market in Germany and Europe.
Meanwhile, talking about the divestment, Kiran Mazumdar-Shaw, MD Biocon said that that since they did the Pfizer deal, the relevance of AxiCorp has changed and that is why it was best possible to move out of the industry.
In 2008, Biocon had taken over 78 per cent stake in AxiCorp by paying $43.7 million. It is now going to sell its shares for about $59.37 million.
As for the Pfizer deal, it happened in October last year when Biocon sold off its global rights to commercialise bio-similar diabetes treatment to it. This was done so that selling the drugs in less-regulated emerging markets was possible.
In its annual Environmental Responsibility Report for fiscal year 2015 released last Thursday, tech giant Apple has revealed that nearly 90 million pounds of unwanted or broken electronics were processed by the company over the last one year….
A new study by the Massachusetts Institute of Technology (MIT) has revealed that Istanbul lies…
The Michael J Fox Foundation is aiming to test wearable sensors in smart watches made by Intel’s…
There was a time just a few years back when Spain ranked second after Greece, as a figure of the euro zone’s huge debt crisis and economic slowdown. The country’s unemployment climbed to a huge twenty seven percent and the economy was still…
In January, trade surplus of Germany decreased since plunge in imports was more than a drop in…
On Tuesday, tech giant Google released latest to show how much of its online traffic is…
German drugmaker Merck said that its experimental cancer medicine evofosfamidehas failed in the last stage of clinical tests due to which it won’t seek regulatory approval for its treatment.
On Monday, Darmstadt, Germany-based Merck said…
In a Tuesday announcement, Adobe revealed that it has...
With the computer business having witnessed steep losses...
In a scenario where the government of the nations are...
After the event that was the 'hot-news' of the week, the...
© 2024 AustrianTribune
